Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked conscientiously but unsuccessfully to develop an one-time therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination treatment in the curing of multi-drug-resistant HIV are actually closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of my last few shares. The first CytoDyn post of mine, “CytoDyn: What To Do When It is Too Good To Be True?”, set away the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such a highly promotional picture in the Uptick Newswire job interview which I came away with an inadequate impression of the business.

Irony of irony, my bad impression of the company has grown steadily, although the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger at the moment still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of this technology as well as associated intellectual property coming from Progenics to CytoDyn, and also approximately 25 million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 million) and also the very first brand new drug application endorsement ($five million), and even royalty payments of 5 % of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and numerous indications, it has this individual therapy as well as a “broad pipeline of indications” as it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy in dozens of indications.

Its opening banner on its website (below) shows an active business with diverse interests albeit focused on leronlimab, several disease sorts, multiple publications and multiple delivering presentations.

Can it all be smoke and mirrors? That’s a question I’ve been asking myself through the very start of the interest of mine in this organization. Judging with the multiples of a huge number of diverse comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this particular question.

CytoDyn is a classic battleground, or maybe some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *